Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase 1, Pharmacokinetics, Maximal Usage Pharmacokinetics, Safety, and Efficacy Study of ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% Administered QD in Adolescent and Pediatric Subjects With Mild to Moderate Atopic Dermatitis

NCT04156191 is registered in ClinicalTrials.gov with Arcutis Biotherapeutics, Inc. as lead sponsor.

NCT NCT04156191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04156191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase 1, Pharmacokinetics, Maximal Usage Pharmacokinetics, Safety, and Efficacy Study of ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% Administered QD in Adolescent and Pediatric Subjects With Mild to Moderate Atopic Dermatitis
Lead sponsor
Arcutis Biotherapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 23, 2019
Completion date
May 2, 2023
Enrollment
101 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis (eczema)